Cargando…
Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action
The clinical development of anticancer metallodrugs is often hindered by the elusive nature of their molecular targets. To identify the molecular targets of an antimetastatic ruthenium organometallic complex based on 1,3,5-triaza-7-phosphaadamantane (RAPTA), we employed a chemical proteomic approach...
Autores principales: | Babak, Maria V., Meier, Samuel M., Huber, Kilian V. M., Reynisson, Jóhannes, Legin, Anton A., Jakupec, Michael A., Roller, Alexander, Stukalov, Alexey, Gridling, Manuela, Bennett, Keiryn L., Colinge, Jacques, Berger, Walter, Dyson, Paul J., Superti-Furga, Giulio, Keppler, Bernhard K., Hartinger, Christian G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Royal Society of Chemistry
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647740/ https://www.ncbi.nlm.nih.gov/pubmed/29308157 http://dx.doi.org/10.1039/c4sc03905j |
Ejemplares similares
-
Affinity Purification Strategies for Proteomic Analysis
of Transcription Factor Complexes
por: Giambruno, Roberto, et al.
Publicado: (2013) -
Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy
por: Huber, Kilian V. M., et al.
Publicado: (2014) -
Proteome-wide small molecule and metabolite interaction mapping
por: Huber, Kilian V. M., et al.
Publicado: (2015) -
A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL
por: Rix, Uwe, et al.
Publicado: (2013) -
A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis
por: Fauster, A, et al.
Publicado: (2015)